Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hisamitsu Pharmaceutical Co ( (JP:4530) ) has provided an announcement.
Hisamitsu Pharmaceutical reported consolidated net sales of ¥114.5 billion for the first nine months of the fiscal year ending February 28, 2026, up 2.9% year on year, while operating profit fell 4.6% to ¥12.6 billion and profit attributable to owners of parent declined 13.0% to ¥11.9 billion, reflecting profit margin pressure despite modest revenue growth. The company’s shareholders’ equity ratio remained high at 78.5%, but net assets declined compared with the end of the previous fiscal year, and it increased the interim dividend to ¥60 per share for FY2026, including a commemorative element tied to the 90th anniversary of SALONPAS®; at the same time, Hisamitsu withdrew its full-year earnings forecast and revised its dividend plan to eliminate the year-end payout in connection with a management buyout and tender offer that is expected to lead to the delisting of its shares, marking a major shift for existing shareholders and public-market stakeholders.
The most recent analyst rating on (JP:4530) stock is a Buy with a Yen4677.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. is a Japan-based pharmaceutical company listed on the Tokyo, Nagoya, and Fukuoka exchanges, best known globally for its SALONPAS® topical analgesic patches. The company focuses on prescription and over-the-counter transdermal products and related pharmaceuticals, serving both domestic and overseas markets.
Average Trading Volume: 183,552
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen328.3B
Find detailed analytics on 4530 stock on TipRanks’ Stock Analysis page.